Imlifidase

Name: Imlifidase in Kidney transplantation in highly sensitized patients: Ongoing post-approval monitoring
Published: 2026-09-14T15:39:06-04:00

Kidney transplantation in highly sensitized patients

Manufacturer: Hansa Biopharma
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment

Ongoing post-approval monitoring

2 evidence topics · 2 sources

European conditional authorization: long-term effectiveness follow-up

“The company that markets Idefirix will provide results of a long-term study of Idefirix to confirm its effectiveness.” (opens the source at this quote in a new tab)

Company-reported completion of the post-authorization efficacy study obligation

“the post-authorization obligation has now been fulfilled” (opens the source at this quote in a new tab)